2019
Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
Poorvu PD, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Collins LC, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Jakubowski DM, Russell C, Winer EP, Partridge AH. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. Journal Of Clinical Oncology 2019, 38: 725-733. PMID: 31809240, PMCID: PMC7048163, DOI: 10.1200/jco.19.01959.Peer-Reviewed Original ResearchConceptsNode-positive breast cancerDistant recurrence-free survivalRecurrence scoreBreast cancerBreast Cancer StudyN0 diseaseN1 diseaseYoung womenYoung Women's Breast Cancer StudyPositive/HER2-negative breast cancerHER2-negative breast cancerHuman epidermal growth factor receptorEarly distant recurrenceEarly-stage estrogenN0 breast cancerRS risk groupsNode-positive diseaseMinority of patientsRecurrence-free survivalYears of ageEpidermal growth factor receptorGrowth factor receptorDistant recurrenceAxillary nodesEligible women
2012
Biomarkers of amenorrhea and ovarian function in breast cancer survivors.
Ruddy K, Gelber S, Tamimi R, Ginsburg E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Biomarkers of amenorrhea and ovarian function in breast cancer survivors. Journal Of Clinical Oncology 2012, 30: 9071-9071. DOI: 10.1200/jco.2012.30.15_suppl.9071.Peer-Reviewed Original ResearchAnti-Mullerian hormoneBreast cancer survivorsOvarian functionBreast cancerCancer survivorsProspective multi-center cohort studyFollicle-stimulating hormone levelsMulti-center cohort studyYoung breast cancer survivorsResidual ovarian functionEarly breast cancerLast menstrual periodWilcoxon rank sum testRank sum testOvarian ablationEndocrine therapyOvarian suppressionCohort studyEligible womenFSH levelsOvarian reserveMedian ageOvarian dysfunctionSurvivorship periodMenopausal symptomsQuality of Life in Long-Term Survivors of Metastatic Breast Cancer
Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP, Partridge AH. Quality of Life in Long-Term Survivors of Metastatic Breast Cancer. Clinical Breast Cancer 2012, 12: 119-126. PMID: 22444718, DOI: 10.1016/j.clbc.2012.01.010.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHormone receptor-positive diseaseNode-positive diseaseCancer Therapy-BreastLong-term survivorsSubset of womenHADS anxiety scoreHADS depression scorePopulation of womenFunctional Social Support QuestionnaireFisher's exact testQuality of lifeWilcoxon rank sum testCross-sectional surveyIES-R scaleRank sum testNorth Carolina Functional Social Support QuestionnaireAdjuvant therapyEligible womenPositive diseaseSpearman correlation coefficientDisease characteristicsHospital AnxietyMedical history
2009
Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer.
Ruddy K, Gelber S, Tamimi R, Mayer E, Schapira L, Come S, Meyer M, Winer E, Partridge A. Prevalence and Predictors of Distress in Young Women with Newly Diagnosed Early Stage Breast Cancer. Cancer Research 2009, 69: 1067-1067. DOI: 10.1158/0008-5472.sabcs-09-1067.Peer-Reviewed Original ResearchStage breast cancerBreast cancerOverall distressYoung womenHADS scoresProspective multi-center cohort studyAdvanced-stage breast cancerMulti-center cohort studyEarly-stage breast cancerMultivariate logistic regression modelBaseline surveyOnly sociodemographic factorCentral pathology reviewEarly breast cancerMultivariate logistic regressionPercent of womenCourse of careMedical history itemsLogistic regression modelsBreast cancer diagnosisEligible womenCohort studyMedian agePathology reviewHospital Anxiety